EBEvelien M. J. Beelen

Evelien M. J. Beelen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Evelien M. J. Beelen has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of timing of primary ileocecal resection on prognosis in patients with Crohn’s disease

    by Evelien M J Beelen, Jeanine H C Arkenbosch, Nicole S Erler, Jasmijn A M Sleutjes, Frank Hoentjen, Alexander G L Bodelier, Gerard Dijkstra, Marielle Romberg-Camps, Nanne K de Boer, Laurents P S Stassen, et al.

    Background: The advantage of early ileocecal resection after Crohn’s disease diagnosis is a matter of debate. This study aims to assess the timing of ileocecal resection on prognosis, after correction for possible confounders. Methods: Patients with Crohn's disease with primary ileocecal resection between 2000 and 2019 were included in a retrospective multicentre cohort. The primary endpoint was endoscopic recurrence (Rutgeerts score ≥i2b) within 18 months. Secondary endpoints were escalation of inflammatory bowel disease medication within 18 months and re-resection during follow-up. The association between timing of ileocecal resection and these endpoints was investigated using multivariable proportional hazard models, corrected for covariates including Montreal classification, postoperative prophylaxis, smoking, indication for surgery, medication before ileocecal resection, perianal fistulas, surgical approach, histology, length of resected segment and calendar year. Results: In 822 patients ileocecal resection was performed after a median of 3.1 years (i.q.r. 0.7–8.0) after Crohn's disease diagnosis. The lowest incidence of endoscopic recurrence, escalation of inflammatory bowel disease medication and re-resection was observed for patients undergoing ileocecal resection shortly after diagnosis (0–1 months). After correction for covariates, patients with ileocecal resection at 0, 4 and 12 months after diagnosis had a cumulative incidence of 35 per cent, 48 per cent and 39 per cent for endoscopic recurrence, 20 per cent, 29 per cent and 28 per cent for escalation of inflammatory bowel disease medication and 20 per cent, 30 per cent and 34 per cent for re-resection, respectively. In the multivariable model ileocolonic disease (HR 1.39 (95 per cent c.i. 1.05 to 1.86)), microscopic inflammation of proximal and distal resection margins (HR 2.20 (95 per cent c.i. 1.21 to 3.87)) and postoperative prophylactic biological and immunomodulator (HR 0.16 (95 per cent c.i. 0.05 to 0.43)) were associated with endoscopic recurrence. Conclusion: The timing of ileocecal resection was not associated with a change of disease course; in the multivariable model, the postoperative recurrence was not affected by timing of ileocecal resection.


  • Open Access

    Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials

    by Evelien M.J. Beelen, Daan Nieboer, Jeanine H.C. Arkenbosch, Miguel D. Regueiro, Jack Satsangi, Sandro Ardizzone, Antonio López-Sanromán, Edoardo Savarino, Alessandro Armuzzi, C. Janneke van der Woude, et al.


  • Open Access

    Prophylactic Medication for the Prevention of Endoscopic Recurrence in Crohn’s Disease: a Prospective Study Based on Clinical Risk Stratification

    by Jeanine H C Arkenbosch, Evelien M J Beelen, Gerard Dijkstra, Mariëlle Romberg-Camps, Marjolijn Duijvestein, Frank Hoentjen, Sander van der Marel, P W Jeroen Maljaars, Sita Jansen, Nanne K H de Boer, et al.

    To prevent recurrence after ileocolonic resection [ICR] in Crohn’s disease [CD], postoperative prophylaxis based on risk stratification is recommended in international guidelines. This study aimed to evaluate postoperative CD recurrence after implementation of a clinical management algorithm and to determine the predictive value of clinical and histological risk factors [RFs]. In this multicentre, prospective cohort study, CD patients [≥16 years] scheduled for ICR were included. The algorithm advised no postoperative medication for low-risk patients, and treatment with prophylaxis [immunosuppressant/biological] for high-risk patients [≥1 RF: active smoking, penetrating disease, prior ICR]. Clinical and histological RFs [active inflammation, granulomas, plexitis in resection margins] for endoscopic recurrence [Rutgeerts’ score ≥i2b at 6 months] were assessed using logistic regression and ROC curves based on predicted probabilities. In total, 213 CD patients after ICR were included [age 34.5 years; 65% women] (93 [44%] low-risk; 120 [56%] high-risk: 45 [38%] smoking; 51 [43%] penetrating disease; 51 [43%] prior ICR). Adherence to the algorithm was 82% in low-risk [no prophylaxis] and 51% in high-risk patients [prophylaxis]. Endoscopic recurrence was higher in patients treated without prophylaxis than with prophylaxis in both low [45% vs 16%, p = 0.012] and high-risk patients [49% vs 26%, p = 0.019]. Clinical risk stratification including the prescription of prophylaxis corresponded to an area under the curve [AUC] of 0.70 (95% confidence interval [CI] 0.61–0.79). Clinical RFs combined with histological RFs increased the AUC to 0.73 [95% CI 0.64–0.81]. Adherence to this management algorithm is 65%. Prophylactic medication after ICR prevents endoscopic recurrence in low- and high-risk patients. Clinical risk stratification has an acceptable predictive value, but further refinement is needed.


  • Open Access

    The reproducibility of skeletal muscle signal intensity on routine magnetic resonance imaging in Crohn's disease

    by Corinne E.G.M. Spooren, Toine M. Lodewick, Evelien M.J. Beelen, David P.J. van Dijk, Martijn J.L. Bours, Jeoffrey J. Haans, Ad A.M. Masclee, Marie J. Pierik, Frans C.H. Bakers, Daisy M.A.E. Jonkers

    Background and Aim: Myosteatosis is a prognostic factor in cancer and liver cirrhosis. It can be determined noninvasively using computed tomography or, as shown recently, by magnetic resonance (MR) imaging. The primary aim was to analyze the reproducibility of skeletal muscle signal intensity on routine MR‐enterographies, as indicator of myosteatosis, in Crohn's disease (CD) and to explore the association between skeletal muscle signal intensity at diagnosis with time to intestinal resection.Methods: CD patients undergoing MR‐enterography within 6 months from diagnosis and having a maximum of 5 years follow‐up were included. Skeletal muscle signal intensity was analyzed on T1‐weighted fat‐saturated post‐contrast images. Intra‐observer and inter‐observer reproducibilities were assessed by intra‐class correlation coefficient and Cohen's kappa. Intra‐observer and inter‐observer variabilities were determined by Pearson correlation coefficient and displayed by Bland–Altman plots. Time to intestinal resection was studied by Kaplan–Meier analysis.Results: Median time between diagnosis and MR‐enterography was 5 weeks (inter‐quartile range 1–9) in 35 CD patients. Skeletal muscle signal intensity showed good intra‐class correlation and substantial agreement (for intra‐observer, intraclass correlation coefficient = 0.948, κ = 0.677; and inter‐observer reproducibility, intraclass correlation coefficient = 0.858, κ = 0.622). Resection free survival was shorter in the low skeletal muscle signal intensity group (P = 0.037).Conclusion: Skeletal muscle signal intensity on routine MR‐enterographies is reproducible and was associated with unfavorable disease outcome, indicating potential clinical relevance.


  • Open Access

    Intestinal resection rates in Crohn’s disease decline across two different epidemiological areas: a consistent observation not merely due to introduction of anti-TNFα

    by Evelien M J Beelen, C Janneke van der Woude, Annemarie C de Vries

    With great interest we have read the manuscript written by Murthy et al, published in Gut in June 2019, on the influence of anti-tumour necrosis factor alpha (TNFα) therapy introduction on the rate of hospitalisation and intestinal resection rates in IBD. 1 Despite the difference in the source of data between both studies (Canada: health administrative data and the Netherlands: nationwide pathology database), a declining rate of intestinal resections in Crohn's disease has been confirmed in Canada, at equal rates as the decline that has been observed in the Netherlands. 2 The authors used an advanced statistical method to analyse the impact of anti-TNFα introduction on (among other end points) the rate of intestinal resection. However, in our opinion, the hypothesised direct relationship between introduction of anti-TNFα and a decline in intestinal resection rate is vastly oversimplified for two important reasons. First, several other factors that have influenced both (early) diagnosis and management of Crohn's disease should be taken into account. Important changes over the past decades include improved access to endoscopy, less complications at diagnosis and development of strict and non-invasive monitoring strategies. In their original hypothesis, the authors also state the expectation that


  • Open Access

    Cholecystectomy Risk in Crohn’s Disease Patients After Ileal Resection: a Long-term Nationwide Cohort Study

    by Jorn C. Goet, Evelien M. J. Beelen, Katharina E. Biermann, Annette H. Gijsbers, W. Rudolph Schouten, C. Janneke van der Woude, Annemarie C. de Vries